Recent studies have reported reversal of chemoresistance using an antisense approach to target Bcl-2 in models of chronic lymphocytic leukemia, non-Hodgkins lymphoma, and multiple myeloma79–82. Here, BCL2 is linked to non-Hodgkin lymphoma.